NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.2 Drugs affecting the immune response > 8.2.3 Anti-lymphocyte monoclonal antibodies > Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck - NICE TAG TA473

Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck - NICE TAG TA473

1.1 Cetuximab in combination with platinum-based chemotherapy is recommended as an option for treating recurrent or metastatic squamous cell cancer of the head and neck in adults only:

  • if the cancer started in the oral cavity and

  • when the company provides the drug in line with the commercial access agreement with NHS England.

1.2 These recommendations are not intended to affect treatment with cetuximab that was started within the NHS before this guidance was published. People having treatment outside these recommendations may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

https://www.nice.org.uk/guidance/ta473

Site by Devopa
© Copyright 2019 NHS. All rights reserved.